secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001628280-25-040007
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026
--------------------------------------------------------------------------------

- Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.
- Revenue from royalty agreements $6.3M (vs $169K), including $7.0M ganaxolone royalty monetization with Immedica.
- Cash $38.3M, expected to fund operations into early 2H 2026.
- OV329 Phase 1 topline safety/biomarker results anticipated Q3 2025.
- Company transferred to Nasdaq Capital Market with extended bid price compliance deadline to Feb 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025040007/0001628280-25-040007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025040007/ovid-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-040007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer